{"gene":"ZNF655","run_date":"2026-04-28T23:00:24","timeline":{"discoveries":[{"year":2005,"finding":"ZNF655 (VIK-1) is a Krüppel-like zinc-finger protein that interacts with Vav-1 through the Vav C-SH3 domain and independently binds cyclin-dependent kinase 4 (CDK4) through a separate domain; it shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences, is expressed during G1 phase, and its overexpression inhibits cell-cycle progression in a manner reversed by Vav-1 co-expression.","method":"Yeast two-hybrid screening (Jurkat cDNA library), domain mapping, subcellular localization assays, cell-cycle analysis with overexpression/co-expression experiments","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — reciprocal two-hybrid and domain mapping in single study; functional cell-cycle phenotype confirmed with rescue","pmids":["15558030"],"is_preprint":false},{"year":2020,"finding":"ZNF655 acts as a transcription factor that binds the promoter region of ANKHD1 to suppress its expression, forming part of an ANKHD1/LINC00346/ZNF655 feedback loop in glioma-associated endothelial cells; LINC00346 facilitates Staufen1-mediated mRNA decay (SMD) of ZNF655 mRNA via Alu element pairing, thereby reducing ZNF655 protein and promoting glioma angiogenesis.","method":"Promoter reporter assay (luciferase), RNA immunoprecipitation (RIP), loss/gain-of-function in vitro and in vivo, SMD mechanistic assays","journal":"Molecular therapy. Nucleic acids","confidence":"Medium","confidence_rationale":"Tier 2-3 — multiple orthogonal methods in single study; promoter binding and SMD mechanism demonstrated","pmids":["32464549"],"is_preprint":false},{"year":2021,"finding":"ZNF655 knockdown in NSCLC cells decreases phosphorylation of Akt, downregulates CDK6 and PIK3CA, and upregulates MAPK9, placing ZNF655 upstream of PI3K/Akt signaling; loss of ZNF655 also upregulates pro-apoptotic proteins (Bad, Bax, Fas, Caspase 3, Caspase 8) and cell-cycle inhibitors (p21, p27), linking ZNF655 to apoptosis regulation via PI3K/Akt and p53 pathways.","method":"shRNA knockdown, Western blotting of pathway components, in vitro and in vivo loss-of-function assays","journal":"Life sciences","confidence":"Low","confidence_rationale":"Tier 3 — single lab, pathway placement by protein expression changes without direct mechanistic reconstitution","pmids":["34144060"],"is_preprint":false},{"year":2022,"finding":"ZNF655 functions as a transcription factor that directly binds the promoter of Aurora kinase A (AURKA) to activate its transcription, thereby promoting glioma cell proliferation, survival, and migration; AURKA knockdown partially reverses the pro-tumorigenic effects of ZNF655 overexpression.","method":"ChIP-qPCR, luciferase reporter assay, shRNA knockdown, rescue experiments","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding confirmed by ChIP and luciferase in same study with functional rescue","pmids":["35280721"],"is_preprint":false},{"year":2022,"finding":"ZNF655 promotes binding of transcription factor E2F1 to the CDK1 promoter, increasing CDK1 expression; CDK1 knockdown alleviates the pro-tumorigenic effects of ZNF655 overexpression in pancreatic cancer cells, placing ZNF655 upstream of the E2F1-CDK1 axis.","method":"Co-immunoprecipitation, dual-luciferase reporter assay, ChIP, loss/gain-of-function in vitro and in vivo","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and co-IP with luciferase reporter and rescue experiments in single study","pmids":["35927248"],"is_preprint":false},{"year":2022,"finding":"In gastric cancer, miR-124-3p directly targets the ZNF655 3′UTR to suppress ZNF655 expression, and LINC01210 acts as a ceRNA to sponge miR-124-3p, relieving suppression of ZNF655; this LINC01210/miR-124-3p/ZNF655 axis regulates GC cell proliferation, migration, invasion, and apoptosis.","method":"Dual-luciferase reporter assay, RIP assay, miRNA mimic/inhibitor experiments, rescue assays","journal":"The Kaohsiung journal of medical sciences","confidence":"Low","confidence_rationale":"Tier 3 — single lab, standard ceRNA mechanistic assays without deeper pathway placement","pmids":["36519409"],"is_preprint":false},{"year":2023,"finding":"ZNF655 promotes hepatocellular carcinoma progression through upregulation of PSMB8 (proteasome subunit beta type-8); PSMB8 knockdown weakens the pro-tumorigenic effects of ZNF655 overexpression, placing ZNF655 upstream of PSMB8 in HCC.","method":"Loss/gain-of-function assays, co-expression analysis, rescue experiments with PSMB8 knockdown","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 — functional rescue without direct binding or transcriptional mechanism established","pmids":["37272200"],"is_preprint":false},{"year":2024,"finding":"ZNF655 regulates AKT activation in multiple myeloma; ZNF655 depletion inhibits AKT phosphorylation, cell proliferation, and survival, placing ZNF655 upstream of AKT in MM cells.","method":"shRNA knockdown, Western blotting, in vitro and in vivo loss-of-function assays","journal":"Cell biology international","confidence":"Low","confidence_rationale":"Tier 3 — single lab, pathway placement by expression changes without direct mechanistic reconstitution","pmids":["39491549"],"is_preprint":false},{"year":2025,"finding":"ZNF655 overexpression promotes Akt phosphorylation and Nrf2 nuclear translocation in neurons subjected to OGD/R injury; pharmacological inhibition of Akt or Nrf2 silencing abrogates ZNF655-mediated neuroprotection, placing ZNF655 upstream of the Akt/Nrf2 antioxidant/anti-apoptotic axis.","method":"Adenoviral ZNF655 overexpression, Akt inhibitor, Nrf2 siRNA, Western blotting, TUNEL, DCFH-DA, ELISA","journal":"Brain research","confidence":"Low","confidence_rationale":"Tier 3 — single lab, functional epistasis by inhibitor/siRNA without direct binding or reconstitution","pmids":["41352639"],"is_preprint":false},{"year":2025,"finding":"ZNF655 facilitates nuclear translocation of the MAFF transcription factor in ovarian cancer cells; nuclear MAFF then directly binds the CCND1 (cyclin D1) promoter to activate transcription, and CCND1 mediates ZNF655-dependent proliferation and stemness; ZNF655 overexpression also confers paclitaxel resistance.","method":"Subcellular fractionation/nuclear translocation assay, ChIP (MAFF on CCND1 promoter), luciferase reporter, rescue experiments, xenograft models","journal":"Cancer cell international","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and translocation assays with functional rescue across multiple phenotypes in single study","pmids":["41088232"],"is_preprint":false}],"current_model":"ZNF655 is a C2H2 Krüppel-like zinc-finger transcription factor that shuttles between nucleus and cytoplasm; it directly binds gene promoters (AURKA, CDK1 via E2F1, ANKHD1, CCND1 via MAFF) to activate transcription, interacts with Vav-1 and CDK4 to modulate cell-cycle progression, and activates pro-survival signaling (PI3K/Akt/Nrf2) in multiple cancer and injury contexts."},"narrative":{"teleology":[{"year":2005,"claim":"The initial identification of ZNF655 (VIK-1) established it as a nucleo-cytoplasmic shuttling Krüppel-like zinc-finger protein that physically engages Vav-1 and CDK4 and modulates G1 cell-cycle progression, answering what the gene product is and how it connects to cell-cycle control.","evidence":"Yeast two-hybrid screen, domain mapping, subcellular localization, and cell-cycle analysis in Jurkat-derived system","pmids":["15558030"],"confidence":"Medium","gaps":["No direct DNA-binding target or transcriptional activity demonstrated","Cell-cycle inhibition by overexpression not reconciled with later pro-proliferative roles","Vav-1 and CDK4 interactions not validated by endogenous co-IP"]},{"year":2020,"claim":"Demonstration that ZNF655 binds the ANKHD1 promoter to repress its transcription, and that ZNF655 mRNA is itself degraded via Staufen1-mediated decay triggered by LINC00346, established ZNF655 as a bona fide transcription factor embedded in a lncRNA feedback loop.","evidence":"Luciferase reporter, RIP, SMD assays, and loss/gain-of-function in glioma-associated endothelial cells in vitro and in vivo","pmids":["32464549"],"confidence":"Medium","gaps":["ANKHD1 promoter binding demonstrated by reporter but ChIP-level confirmation not shown","Generalizability of the SMD feedback loop to non-endothelial contexts unclear"]},{"year":2021,"claim":"Knockdown studies in NSCLC placed ZNF655 upstream of PI3K/Akt signaling and apoptotic regulators, revealing a broader pro-survival signaling role beyond direct transcriptional targets.","evidence":"shRNA knockdown with Western blot profiling of Akt, CDK6, PIK3CA, p21, p27, caspases in NSCLC cells","pmids":["34144060"],"confidence":"Low","gaps":["Pathway positioning inferred from expression changes without direct binding or reconstitution","No identification of direct transcriptional targets mediating PI3K/Akt activation","Single-lab study"]},{"year":2022,"claim":"ChIP and reporter assays proved ZNF655 directly activates the AURKA promoter and cooperates with E2F1 at the CDK1 promoter, defining two key mitotic-kinase targets through which ZNF655 drives proliferation in glioma and pancreatic cancer.","evidence":"ChIP-qPCR, luciferase reporters, co-IP of ZNF655–E2F1, functional rescue by AURKA or CDK1 knockdown","pmids":["35280721","35927248"],"confidence":"Medium","gaps":["DNA-binding motif or genome-wide binding profile not defined","Whether ZNF655–E2F1 interaction is direct or bridged by co-factors is unresolved","Relevance of these targets in non-cancer physiology unknown"]},{"year":2023,"claim":"Identification of PSMB8 as a downstream effector in hepatocellular carcinoma expanded the repertoire of ZNF655-regulated genes, though direct transcriptional regulation was not established.","evidence":"Overexpression/knockdown rescue experiments in HCC cell lines","pmids":["37272200"],"confidence":"Low","gaps":["No ChIP or reporter assay to confirm direct promoter binding of PSMB8","Single-lab functional data without independent replication"]},{"year":2025,"claim":"Two studies extended ZNF655 function: one showed ZNF655 promotes MAFF nuclear translocation and CCND1 transcription in ovarian cancer conferring paclitaxel resistance, the other showed ZNF655 activates Akt/Nrf2 antioxidant signaling in neurons, broadening ZNF655's role from an oncogenic factor to a general pro-survival transcriptional regulator.","evidence":"ChIP of MAFF on CCND1 promoter, subcellular fractionation, xenografts (ovarian cancer); adenoviral overexpression, Akt inhibitor/Nrf2 siRNA epistasis in OGD/R neuronal model","pmids":["41088232","41352639"],"confidence":"Medium","gaps":["How ZNF655 promotes MAFF nuclear translocation mechanistically is unknown","Direct binding of ZNF655 to Akt pathway components not demonstrated","Nrf2 axis role relies on pharmacological/siRNA epistasis without direct interaction data"]},{"year":null,"claim":"The genome-wide binding landscape and consensus DNA-binding motif for ZNF655 remain undefined, and how its early-described G1-inhibitory phenotype relates to its consistently observed pro-proliferative role in cancer contexts is unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No ChIP-seq or equivalent genome-wide binding data available","The structural basis for target promoter selectivity is unknown","Physiological (non-cancer) function of ZNF655 has not been addressed in knockout models"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,3,4,9]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,3,4,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,7,8]}],"complexes":[],"partners":["VAV1","CDK4","E2F1","MAFF","AURKA","ANKHD1"],"other_free_text":[]},"mechanistic_narrative":"ZNF655 is a Krüppel-type C2H2 zinc-finger transcription factor that promotes cell-cycle progression and cell survival by directly activating transcription of proliferative and oncogenic target genes. It shuttles between nucleus and cytoplasm via dedicated NLS/NES sequences, interacts with Vav-1 and CDK4, and its overexpression inhibits G1 progression in a manner rescued by Vav-1 co-expression [PMID:15558030]. ZNF655 directly binds promoters of AURKA and ANKHD1, cooperates with E2F1 to activate CDK1 transcription, and facilitates MAFF nuclear translocation to drive CCND1 expression [PMID:35280721, PMID:35927248, PMID:32464549, PMID:41088232]. Across multiple cancer types and neuronal injury models, ZNF655 sustains PI3K/Akt signaling and suppresses apoptosis, linking its transcriptional activity to pro-survival pathway output [PMID:34144060, PMID:41352639]."},"prefetch_data":{"uniprot":{"accession":"Q8N720","full_name":"Zinc finger protein 655","aliases":["Vav-interacting Krueppel-like protein"],"length_aa":491,"mass_kda":57.4,"function":"Probable transcription factor","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8N720/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF655","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"INTS14","stoichiometry":4.0},{"gene":"POLR2K","stoichiometry":0.2},{"gene":"SSRP1","stoichiometry":0.2},{"gene":"SUPT5H","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF655","total_profiled":1310},"omim":[{"mim_id":"617891","title":"ZINC FINGER PROTEIN 655; ZNF655","url":"https://www.omim.org/entry/617891"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF655"},"hgnc":{"alias_symbol":["VIK-1","VIK"],"prev_symbol":[]},"alphafold":{"accession":"Q8N720","domains":[{"cath_id":"3.30.160.60","chopping":"211-264","consensus_level":"medium","plddt":76.6765,"start":211,"end":264},{"cath_id":"3.30.160.60","chopping":"300-351","consensus_level":"medium","plddt":67.8765,"start":300,"end":351},{"cath_id":"3.30.160.60","chopping":"379-454","consensus_level":"medium","plddt":65.798,"start":379,"end":454}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N720","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N720-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8N720-F1-predicted_aligned_error_v6.png","plddt_mean":53.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF655","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF655"},"sequence":{"accession":"Q8N720","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8N720.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8N720/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8N720"}},"corpus_meta":[{"pmid":"19000166","id":"PMC_19000166","title":"VH1/BRL2 receptor-like kinase interacts with vascular-specific adaptor proteins VIT and VIK to influence leaf venation.","date":"2008","source":"The Plant journal : for cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19000166","citation_count":58,"is_preprint":false},{"pmid":"32464549","id":"PMC_32464549","title":"Role of ANKHD1/LINC00346/ZNF655 Feedback Loop in Regulating the Glioma Angiogenesis via Staufen1-Mediated mRNA Decay.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/32464549","citation_count":36,"is_preprint":false},{"pmid":"8380921","id":"PMC_8380921","title":"The murine vik gene (chromosome 9) encodes a putative receptor with unique protein kinase motifs.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8380921","citation_count":22,"is_preprint":false},{"pmid":"28554562","id":"PMC_28554562","title":"Identification and pathotypical analysis of a novel VIk sub-genotype Newcastle disease virus obtained from pigeon in China.","date":"2017","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/28554562","citation_count":20,"is_preprint":false},{"pmid":"15558030","id":"PMC_15558030","title":"Characterization of VIK-1: a new Vav-interacting Kruppel-like protein.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15558030","citation_count":18,"is_preprint":false},{"pmid":"35927248","id":"PMC_35927248","title":"ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1.","date":"2022","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/35927248","citation_count":17,"is_preprint":false},{"pmid":"38958531","id":"PMC_38958531","title":"VIK-Mediated Auxin Signaling Regulates Lateral Root Development in Arabidopsis.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38958531","citation_count":11,"is_preprint":false},{"pmid":"34144060","id":"PMC_34144060","title":"ZNF655 is involved in development and progression of non-small-cell lung cancer.","date":"2021","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34144060","citation_count":10,"is_preprint":false},{"pmid":"35280721","id":"PMC_35280721","title":"ZNF655 Promotes the Progression of Glioma Through Transcriptional Regulation of AURKA.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35280721","citation_count":8,"is_preprint":false},{"pmid":"37272200","id":"PMC_37272200","title":"ZNF655 promotes the progression of hepatocellular carcinoma through PSMB8.","date":"2023","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/37272200","citation_count":7,"is_preprint":false},{"pmid":"36519409","id":"PMC_36519409","title":"ZNF655 mediated by LINC01210/miR-124-3p axis promotes the progression of gastric cancer.","date":"2022","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36519409","citation_count":5,"is_preprint":false},{"pmid":"41352639","id":"PMC_41352639","title":"ZNF655-mediated neuroprotection in cerebral ischemia-reperfusion injury via Akt/Nrf2 pathway modulation.","date":"2025","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/41352639","citation_count":1,"is_preprint":false},{"pmid":"39491549","id":"PMC_39491549","title":"ZNF655 involved in the progression of multiple myeloma via the activation of AKT.","date":"2024","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/39491549","citation_count":1,"is_preprint":false},{"pmid":"40576591","id":"PMC_40576591","title":"Regulation of the immunity-related VIK-APK-EDS1 pathway in Medicago for resistance to Phytophthora.","date":"2025","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/40576591","citation_count":0,"is_preprint":false},{"pmid":"41088232","id":"PMC_41088232","title":"ZNF655 promotes tumor growth and chemoresistance by targeting MAFF-CCND1 axis in ovarian cancer.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/41088232","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8498,"output_tokens":2472,"usd":0.031287},"stage2":{"model":"claude-opus-4-6","input_tokens":5786,"output_tokens":2072,"usd":0.121095},"total_usd":0.152382,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"ZNF655 (VIK-1) is a Krüppel-like zinc-finger protein that interacts with Vav-1 through the Vav C-SH3 domain and independently binds cyclin-dependent kinase 4 (CDK4) through a separate domain; it shuttles between nucleus and cytoplasm via functional nuclear localization and export sequences, is expressed during G1 phase, and its overexpression inhibits cell-cycle progression in a manner reversed by Vav-1 co-expression.\",\n      \"method\": \"Yeast two-hybrid screening (Jurkat cDNA library), domain mapping, subcellular localization assays, cell-cycle analysis with overexpression/co-expression experiments\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal two-hybrid and domain mapping in single study; functional cell-cycle phenotype confirmed with rescue\",\n      \"pmids\": [\"15558030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF655 acts as a transcription factor that binds the promoter region of ANKHD1 to suppress its expression, forming part of an ANKHD1/LINC00346/ZNF655 feedback loop in glioma-associated endothelial cells; LINC00346 facilitates Staufen1-mediated mRNA decay (SMD) of ZNF655 mRNA via Alu element pairing, thereby reducing ZNF655 protein and promoting glioma angiogenesis.\",\n      \"method\": \"Promoter reporter assay (luciferase), RNA immunoprecipitation (RIP), loss/gain-of-function in vitro and in vivo, SMD mechanistic assays\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — multiple orthogonal methods in single study; promoter binding and SMD mechanism demonstrated\",\n      \"pmids\": [\"32464549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ZNF655 knockdown in NSCLC cells decreases phosphorylation of Akt, downregulates CDK6 and PIK3CA, and upregulates MAPK9, placing ZNF655 upstream of PI3K/Akt signaling; loss of ZNF655 also upregulates pro-apoptotic proteins (Bad, Bax, Fas, Caspase 3, Caspase 8) and cell-cycle inhibitors (p21, p27), linking ZNF655 to apoptosis regulation via PI3K/Akt and p53 pathways.\",\n      \"method\": \"shRNA knockdown, Western blotting of pathway components, in vitro and in vivo loss-of-function assays\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pathway placement by protein expression changes without direct mechanistic reconstitution\",\n      \"pmids\": [\"34144060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF655 functions as a transcription factor that directly binds the promoter of Aurora kinase A (AURKA) to activate its transcription, thereby promoting glioma cell proliferation, survival, and migration; AURKA knockdown partially reverses the pro-tumorigenic effects of ZNF655 overexpression.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, shRNA knockdown, rescue experiments\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding confirmed by ChIP and luciferase in same study with functional rescue\",\n      \"pmids\": [\"35280721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF655 promotes binding of transcription factor E2F1 to the CDK1 promoter, increasing CDK1 expression; CDK1 knockdown alleviates the pro-tumorigenic effects of ZNF655 overexpression in pancreatic cancer cells, placing ZNF655 upstream of the E2F1-CDK1 axis.\",\n      \"method\": \"Co-immunoprecipitation, dual-luciferase reporter assay, ChIP, loss/gain-of-function in vitro and in vivo\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and co-IP with luciferase reporter and rescue experiments in single study\",\n      \"pmids\": [\"35927248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In gastric cancer, miR-124-3p directly targets the ZNF655 3′UTR to suppress ZNF655 expression, and LINC01210 acts as a ceRNA to sponge miR-124-3p, relieving suppression of ZNF655; this LINC01210/miR-124-3p/ZNF655 axis regulates GC cell proliferation, migration, invasion, and apoptosis.\",\n      \"method\": \"Dual-luciferase reporter assay, RIP assay, miRNA mimic/inhibitor experiments, rescue assays\",\n      \"journal\": \"The Kaohsiung journal of medical sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, standard ceRNA mechanistic assays without deeper pathway placement\",\n      \"pmids\": [\"36519409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF655 promotes hepatocellular carcinoma progression through upregulation of PSMB8 (proteasome subunit beta type-8); PSMB8 knockdown weakens the pro-tumorigenic effects of ZNF655 overexpression, placing ZNF655 upstream of PSMB8 in HCC.\",\n      \"method\": \"Loss/gain-of-function assays, co-expression analysis, rescue experiments with PSMB8 knockdown\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional rescue without direct binding or transcriptional mechanism established\",\n      \"pmids\": [\"37272200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF655 regulates AKT activation in multiple myeloma; ZNF655 depletion inhibits AKT phosphorylation, cell proliferation, and survival, placing ZNF655 upstream of AKT in MM cells.\",\n      \"method\": \"shRNA knockdown, Western blotting, in vitro and in vivo loss-of-function assays\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pathway placement by expression changes without direct mechanistic reconstitution\",\n      \"pmids\": [\"39491549\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF655 overexpression promotes Akt phosphorylation and Nrf2 nuclear translocation in neurons subjected to OGD/R injury; pharmacological inhibition of Akt or Nrf2 silencing abrogates ZNF655-mediated neuroprotection, placing ZNF655 upstream of the Akt/Nrf2 antioxidant/anti-apoptotic axis.\",\n      \"method\": \"Adenoviral ZNF655 overexpression, Akt inhibitor, Nrf2 siRNA, Western blotting, TUNEL, DCFH-DA, ELISA\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, functional epistasis by inhibitor/siRNA without direct binding or reconstitution\",\n      \"pmids\": [\"41352639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF655 facilitates nuclear translocation of the MAFF transcription factor in ovarian cancer cells; nuclear MAFF then directly binds the CCND1 (cyclin D1) promoter to activate transcription, and CCND1 mediates ZNF655-dependent proliferation and stemness; ZNF655 overexpression also confers paclitaxel resistance.\",\n      \"method\": \"Subcellular fractionation/nuclear translocation assay, ChIP (MAFF on CCND1 promoter), luciferase reporter, rescue experiments, xenograft models\",\n      \"journal\": \"Cancer cell international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and translocation assays with functional rescue across multiple phenotypes in single study\",\n      \"pmids\": [\"41088232\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF655 is a C2H2 Krüppel-like zinc-finger transcription factor that shuttles between nucleus and cytoplasm; it directly binds gene promoters (AURKA, CDK1 via E2F1, ANKHD1, CCND1 via MAFF) to activate transcription, interacts with Vav-1 and CDK4 to modulate cell-cycle progression, and activates pro-survival signaling (PI3K/Akt/Nrf2) in multiple cancer and injury contexts.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZNF655 is a Krüppel-type C2H2 zinc-finger transcription factor that promotes cell-cycle progression and cell survival by directly activating transcription of proliferative and oncogenic target genes. It shuttles between nucleus and cytoplasm via dedicated NLS/NES sequences, interacts with Vav-1 and CDK4, and its overexpression inhibits G1 progression in a manner rescued by Vav-1 co-expression [PMID:15558030]. ZNF655 directly binds promoters of AURKA and ANKHD1, cooperates with E2F1 to activate CDK1 transcription, and facilitates MAFF nuclear translocation to drive CCND1 expression [PMID:35280721, PMID:35927248, PMID:32464549, PMID:41088232]. Across multiple cancer types and neuronal injury models, ZNF655 sustains PI3K/Akt signaling and suppresses apoptosis, linking its transcriptional activity to pro-survival pathway output [PMID:34144060, PMID:41352639].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"The initial identification of ZNF655 (VIK-1) established it as a nucleo-cytoplasmic shuttling Krüppel-like zinc-finger protein that physically engages Vav-1 and CDK4 and modulates G1 cell-cycle progression, answering what the gene product is and how it connects to cell-cycle control.\",\n      \"evidence\": \"Yeast two-hybrid screen, domain mapping, subcellular localization, and cell-cycle analysis in Jurkat-derived system\",\n      \"pmids\": [\"15558030\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No direct DNA-binding target or transcriptional activity demonstrated\",\n        \"Cell-cycle inhibition by overexpression not reconciled with later pro-proliferative roles\",\n        \"Vav-1 and CDK4 interactions not validated by endogenous co-IP\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that ZNF655 binds the ANKHD1 promoter to repress its transcription, and that ZNF655 mRNA is itself degraded via Staufen1-mediated decay triggered by LINC00346, established ZNF655 as a bona fide transcription factor embedded in a lncRNA feedback loop.\",\n      \"evidence\": \"Luciferase reporter, RIP, SMD assays, and loss/gain-of-function in glioma-associated endothelial cells in vitro and in vivo\",\n      \"pmids\": [\"32464549\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"ANKHD1 promoter binding demonstrated by reporter but ChIP-level confirmation not shown\",\n        \"Generalizability of the SMD feedback loop to non-endothelial contexts unclear\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Knockdown studies in NSCLC placed ZNF655 upstream of PI3K/Akt signaling and apoptotic regulators, revealing a broader pro-survival signaling role beyond direct transcriptional targets.\",\n      \"evidence\": \"shRNA knockdown with Western blot profiling of Akt, CDK6, PIK3CA, p21, p27, caspases in NSCLC cells\",\n      \"pmids\": [\"34144060\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Pathway positioning inferred from expression changes without direct binding or reconstitution\",\n        \"No identification of direct transcriptional targets mediating PI3K/Akt activation\",\n        \"Single-lab study\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ChIP and reporter assays proved ZNF655 directly activates the AURKA promoter and cooperates with E2F1 at the CDK1 promoter, defining two key mitotic-kinase targets through which ZNF655 drives proliferation in glioma and pancreatic cancer.\",\n      \"evidence\": \"ChIP-qPCR, luciferase reporters, co-IP of ZNF655–E2F1, functional rescue by AURKA or CDK1 knockdown\",\n      \"pmids\": [\"35280721\", \"35927248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"DNA-binding motif or genome-wide binding profile not defined\",\n        \"Whether ZNF655–E2F1 interaction is direct or bridged by co-factors is unresolved\",\n        \"Relevance of these targets in non-cancer physiology unknown\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of PSMB8 as a downstream effector in hepatocellular carcinoma expanded the repertoire of ZNF655-regulated genes, though direct transcriptional regulation was not established.\",\n      \"evidence\": \"Overexpression/knockdown rescue experiments in HCC cell lines\",\n      \"pmids\": [\"37272200\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No ChIP or reporter assay to confirm direct promoter binding of PSMB8\",\n        \"Single-lab functional data without independent replication\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Two studies extended ZNF655 function: one showed ZNF655 promotes MAFF nuclear translocation and CCND1 transcription in ovarian cancer conferring paclitaxel resistance, the other showed ZNF655 activates Akt/Nrf2 antioxidant signaling in neurons, broadening ZNF655's role from an oncogenic factor to a general pro-survival transcriptional regulator.\",\n      \"evidence\": \"ChIP of MAFF on CCND1 promoter, subcellular fractionation, xenografts (ovarian cancer); adenoviral overexpression, Akt inhibitor/Nrf2 siRNA epistasis in OGD/R neuronal model\",\n      \"pmids\": [\"41088232\", \"41352639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"How ZNF655 promotes MAFF nuclear translocation mechanistically is unknown\",\n        \"Direct binding of ZNF655 to Akt pathway components not demonstrated\",\n        \"Nrf2 axis role relies on pharmacological/siRNA epistasis without direct interaction data\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The genome-wide binding landscape and consensus DNA-binding motif for ZNF655 remain undefined, and how its early-described G1-inhibitory phenotype relates to its consistently observed pro-proliferative role in cancer contexts is unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No ChIP-seq or equivalent genome-wide binding data available\",\n        \"The structural basis for target promoter selectivity is unknown\",\n        \"Physiological (non-cancer) function of ZNF655 has not been addressed in knockout models\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 3, 4, 9]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 3, 4, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 7, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"VAV1\",\n      \"CDK4\",\n      \"E2F1\",\n      \"MAFF\",\n      \"AURKA\",\n      \"ANKHD1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}